What is the role of CNS prophylaxis in the treatment of Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL)?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

CNS prophylaxis using intrathecal methotrexate with or without cytarabine and hydrocortisone is included in most regimens. Without CNS prophylaxis, 30-50% of patients will develop CNS relapse. With the above mentioned regimens, the rate of CNS relapse drops to about 6-11%. [57] Use of prophylactic cranial irradiation causes increased neurologic toxicity; in the 2004 update of the CALGB 9251, the protocol was amended to restrict its use to patients with bone marrow involvement only. This did not significantly affect the rate of CNS relapse.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!